

Supplementary Table 7. Adjusted IRRs (95% CIs) of selected factors for major GI bleeding following AIS

	Time intervals elapsed since the onset of index stroke						
	≤1 month	2–3 months	4–6 months	7–12 months	2nd year	3rd year	>3 years
Female sex	0.83 (0.59–1.17)	0.71 (0.49–1.02)	0.75 (0.52–1.07)	0.93 (0.64–1.36)	0.97 (0.72–1.29)	0.93 (0.67–1.31)	0.94 (0.65–1.35)
Age, ≥75	0.89 (0.62–1.26)	1.18 (0.83–1.69)	1.13 (0.79–1.62)	1.53 (1.06–2.22)	1.39 (1.03–1.87)	1.85 (1.32–2.60)	2.16 (1.49–3.11)
Smoking	1.34 (0.87–2.07)	1.13 (0.72–1.78)	1.35 (0.90–2.05)	1.29 (0.82–2.01)	1.09 (0.77–1.52)	1.23 (0.84–1.82)	1.26 (0.82–1.94)
Initial NIHSS							
5–14	0.92 (0.61–1.38)	1.20 (0.79–1.82)	1.23 (0.84–1.83)	1.20 (0.80–1.79)	0.82 (0.59–1.13)	1.15 (0.80–1.66)	0.78 (0.52–1.18)
≥15	0.96 (0.60–1.54)	1.21 (0.71–2.05)	0.90 (0.53–1.52)	0.88 (0.50–1.56)	0.80 (0.48–1.32)	0.65 (0.37–1.15)	0.54 (0.28–1.05)
IV tPA	0.99 (0.61–1.60)	0.91 (0.54–1.52)	0.90 (0.53–1.52)	0.97 (0.59–1.59)	0.96 (0.65–1.40)	0.65 (0.39–1.08)	0.96 (0.57–1.61)
History of gastroduodenal ulcer	0.87 (0.59–1.28)	0.90 (0.60–1.35)	1.27 (0.83–1.93)	1.74 (1.10–2.76)	1.17 (0.81–1.68)	1.39 (0.92–2.10)	2.17 (1.37–3.42)
History of gastrointestinal hemorrhage	1.32 (0.79–2.21)	1.31 (0.74–2.29)	1.48 (0.85–2.58)	1.17 (0.64–2.14)	1.84 (1.24–2.72)	1.33 (0.79–2.24)	1.32 (0.70–2.51)
Long-term NSAID use	1.29 (0.95–1.76)	0.92 (0.66–1.29)	1.31 (0.95–1.81)	1.18 (0.87–1.61)	0.92 (0.71–1.18)	1.67 (1.24–2.25)	1.09 (0.77–1.54)
Chronic alcohol use	1.50 (0.74–3.07)	1.04 (0.43–2.55)	0.44 (0.11–1.76)	1.16 (0.51–2.61)	0.92 (0.45–1.85)	1.22 (0.57–2.59)	1.30 (0.57–2.96)
Anemia							
Mild	2.04 (1.26–3.28)	1.67 (1.04–2.68)	2.01 (1.31–3.07)	2.57 (1.63–4.06)	1.83 (1.29–2.60)	2.05 (1.36–3.08)	2.49 (1.64–3.78)
Moderate to severe	7.25 (4.85–10.82)	3.85 (2.55–5.83)	2.98 (1.90–4.68)	3.87 (2.43–6.18)	4.12 (2.88–5.90)	3.01 (1.89–4.80)	3.88 (2.32–6.50)
eGFR (mL/min/1.73 m ²)							
60–89	1.12 (0.74–1.71)	1.38 (0.86–2.23)	1.47 (0.94–2.29)	1.27 (0.81–2.00)	1.65 (1.16–2.36)	1.26 (0.82–1.92)	1.40 (0.92–2.11)
30–59	1.27 (0.80–2.00)	2.28 (1.43–3.64)	1.30 (0.78–2.18)	1.20 (0.72–2.02)	2.34 (1.54–3.56)	2.20 (1.39–3.48)	2.14 (1.31–3.49)
<30	1.04 (0.52–2.12)	3.20 (1.71–5.98)	3.51 (1.97–6.25)	2.94 (1.59–5.45)	3.36 (1.90–5.92)	3.05 (1.57–5.91)	1.62 (0.51–5.15)
Antithrombotics at discharge							
Other AP mono	2.35 (1.37–4.02)	1.01 (0.50–2.05)	1.30 (0.72–2.34)	1.00 (0.45–2.23)	1.43 (0.90–2.25)	0.74 (0.37–1.52)	1.84 (0.97–3.48)
Dual AP or more	1.28 (0.80–2.04)	1.38 (0.86–2.23)	0.72 (0.44–1.17)	1.55 (0.92–2.63)	1.09 (0.75–1.57)	1.20 (0.78–1.82)	1.44 (0.86–2.40)
AC without AP	0.50 (0.25–1.03)	1.29 (0.75–2.22)	1.17 (0.69–1.98)	1.63 (0.92–2.89)	1.10 (0.71–1.68)	1.63 (1.00–2.64)	2.17 (1.23–3.83)
AC with AP	1.00 (0.44–2.27)	1.59 (0.76–3.32)	1.50 (0.77–2.92)	2.46 (1.25–4.86)	1.90 (0.98–3.68)	1.01 (0.45–2.27)	1.62 (0.73–3.61)
No treatment	3.22 (1.85–5.59)	2.19 (1.13–4.23)	0.98 (0.46–2.06)	2.13 (0.99–4.55)	1.68 (0.83–3.42)	0.86 (0.38–1.94)	0.92 (0.29–2.96)
3-month mRS							
1	0.71 (0.35–1.46)	1.41 (0.59–3.33)	0.84 (0.45–1.59)	0.57 (0.28–1.18)	0.83 (0.53–1.30)	1.16 (0.68–1.99)	0.94 (0.56–1.57)
2	1.42 (0.74–2.72)	2.46 (1.08–5.59)	1.17 (0.63–2.18)	1.38 (0.72–2.64)	1.27 (0.81–1.99)	1.86 (1.10–3.13)	1.31 (0.77–2.25)
3	1.11 (0.51–2.43)	2.40 (1.03–5.57)	1.63 (0.89–2.99)	1.43 (0.73–2.82)	2.09 (1.33–3.29)	1.56 (0.86–2.82)	1.14 (0.63–2.05)
4	2.59 (1.38–4.87)	6.01 (2.79–12.98)	2.20 (1.20–4.06)	2.24 (1.19–4.21)	2.01 (1.27–3.16)	2.35 (1.29–4.31)	1.65 (0.87–3.14)
5–6	4.30 (2.49–7.41)	12.94 (6.28–26.63)	4.88 (2.72–8.77)	4.24 (2.20–8.18)	3.03 (1.67–5.48)	4.86 (2.54–9.30)	2.58 (1.28–5.19)

Adjusted IRR (95% CI) of major GI bleeding were calculated using the Fine-Gray competing risk model for sub-distribution hazard with death as a competing risk. Reference group: sex (male), age (<75 years), smoking (no), initial NIHSS (0–4), IV tPA (no), histories of gastroduodenal ulcer (no), gastrointestinal hemorrhage (no), long-term NSAID use (no), chronic alcohol use (no), anemia (none), eGFR (≥90 mL/min/1.73 m²), antithrombotics at discharge (ASA mono), and 3-month mRS (0).

IRR, incidence rate ratio; CI, confidence interval; GI, gastrointestinal; AIS, acute ischemic stroke; NIHSS, National Institutes of Health Stroke Scale; IV tPA, intravenous tissue plasminogen activator; NSAID, nonsteroidal anti-inflammatory drug; eGFR, estimated glomerular filtration rate; ASA, aspirin; AP, antiplatelets; AC, anticoagulants; mRS, modified Rankin Scale.